News from Zyme and the companies we work with.

February 20, 19

Owlstone Medical Partners with Shanghai Renji Hospital to Pioneer Breath Biopsy Lung Cancer Trial in China

Cambridge, UK, and Shanghai, China, February 20 2019:  Owlstone Medical Ltd., a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, and Renji Hospital, today announced a collaboration to conduct a clinical trial into … Continue reading →

February 20, 19

Mogrify raises $3.7 million USD seed funding to accelerate its mission to transform cell therapy via direct cellular conversion

Darrin M Disley, PhD, DSc, OBE, appointed as CEO New investment from Ahren Innovation Capital, 24Haymarket and Dr Disley Mogrify’s technology enables the conversion of any mature cell type into any other mature cell type without going through a pluripotent … Continue reading →

February 13, 19

Chemspace and LabNetwork collaborate to extend access to chemical databases

Collaboration provides drug discovery researchers access to European distribution and local support for library of in-stock and on-demand compounds Riga, Latvia and Shanghai, China, February 13 2019: Chemspace and LabNetwork, a WuXi AppTec company, both online marketplaces for chemical compounds … Continue reading →

February 7, 19

Bio-Rad Introduces Anti-Eculizumab Antibodies

HERCULES, Calif.–February 7, 2019–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of a range of recombinant monoclonal anti-idiotypic antibodies that inhibit the binding of eculizumab (Soliris) … Continue reading →

February 5, 19

Aigenpulse Receives ISO 9001:2015 and ISO 27001:2013 Certification for AI Data Technology

Certification affirms commitment to providing highest standards of quality and information security  Oxford, UK, 5th February 2019: Aigenpulse Ltd., (Aigenpulse), a big data technology company which specialises in structuring, integrating and deriving meaning from large, disparate data assets, today announced … Continue reading →

February 4, 19

Moderna exercises option for an exclusive product license with Avacta Group plc

Cambridge, UK, 04 February 2019: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that ModernaTX, Inc. (NASDAQ: MRNA) has exercised its option to enter into an exclusive licensing agreement with respect to … Continue reading →

January 29, 19

Metrion Biosciences and LifeArc sign collaboration agreement for neuroscience-focused ion channel drug discovery

Novel small molecule programme aims to address major unmet medical need in neuroscience Collaboration focused on specific potassium ion channel target Cambridge and London, UK, 29 January 2019: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery … Continue reading →

January 29, 19

Sphere Fluidics closes $2 million USD (c. £1.5 million GBP) investment round

Investment received from Greenwood Way Capital, Oxford Technology and Innovations EIS Fund and 24Haymarket Funding will be used to accelerate growth in operations and sales across the UK and USA Cambridge, UK, 29 January 2019: Sphere Fluidics, a company commercializing … Continue reading →

January 28, 19

Horizon Discovery and Rutgers University form exclusive partnership to develop next generation novel gene editing technology

Horizon will work with Rutgers University to develop and commercialise base editing platform for therapeutic and research applications New gene editing technology builds on CRISPR and has the potential to assist in the development and treatment of a number of … Continue reading →

January 28, 19

Optibrium strengthens senior management team with Financial Director appointment

CAMBRIDGE, UK, 28 January 2019 – Optibrium™, a developer of software for drug discovery, today announced the appointment of Clare Devlin as Financial Director. The new role supports the company’s sustained rapid growth and ambitious expansion plans, driven by the … Continue reading →